Skip to main content
. Author manuscript; available in PMC: 2011 May 10.
Published in final edited form as: Lancet. 2011 Feb 25;377(9768):813–822. doi: 10.1016/S0140-6736(10)62344-6

Table 2.

Patients with first on-study skeletal-related events by type

Zoledronic acid
(n=951)
Denosumab
(n=950)
Total confirmed events 386 (41%) 341 (36%)

Radiation to bone 203 (21%) 177 (19%)

Pathological fracture 143 (15%) 137 (14%)

Spinal cord compression 36 (4%) 26 (3%)

Surgery to bone 4 (<1%) 1 (<1%)

Data are number (%).